Get the Stockscreener App
71.65
0.47%
-0.34
After Hours:
71.65
Disc Medicine Inc stock is traded at $71.65, with a volume of 400.42K.
It is down -0.47% in the last 24 hours and down -9.33% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$71.99
Open:
$72.42
24h Volume:
400.42K
Relative Volume:
0.71
Market Cap:
$2.70B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-19.52
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
-8.53%
1M Performance:
-9.33%
6M Performance:
+21.38%
1Y Performance:
+33.58%
1-Day Range:
$70.60
$73.67
1-Week Range:
$70.60
$81.28
52-Week Range:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
71.65 | 2.72B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out - ACCESS Newswire
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
getLinesFromResByArray error: size == 0 - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - ACCESS Newswire
Hedge Fund Bets: Whats the beta of Disc Medicine Inc stockJuly 2025 Action & Entry Point Confirmation Alerts - baoquankhu1.vn
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
Trend Review: Will Disc Medicine Inc outperform during market rallies2025 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Responsive Playbooks and the IRON Inflection - Stock Traders Daily
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect | NDAQ:IRON | Press Release - Stockhouse
Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BMO Capital reaffirms Disc Medicine stock rating amid approval optimism By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Investors to Inquire about Securities Investigation - accessnewswire.com
Y Intercept Hong Kong Ltd Purchases 33,905 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade - Yahoo Finance
Disc Medicine, Inc. (IRON) Stock Analysis: Biotech Innovator With A 57% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Investors to Reach Out - ACCESS Newswire
Report of FDA Drug Approval Delay is 'Likely Noise': Analyst - streetwisereports.com
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON - Chartmill
Bear Alert: What is Disc Medicine Inc. s debt to equity ratioJuly 2025 Catalysts & Accurate Intraday Trade Tips - baoquankhu1.vn
HC Wainwright Weighs in on Disc Medicine FY2030 Earnings - MarketBeat
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
iA Global Asset Management Inc. Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Understanding the Setup: (IRON) and Scalable Risk - Stock Traders Daily
Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,000 Shares of Stock - MarketBeat
The Bull Case For Disc Medicine (IRON) Could Change Following FDA Review Delay And New HR Chief Appointment - Sahm
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Is Disc Medicine Inc. attractive at current valuationWeekly Market Outlook & High Win Rate Trade Alerts - bollywoodhelpline.com
Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus - Sahm
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON) - The Globe and Mail
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8% - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA ActionDisc Medicine (NASDAQ:IRON) - Benzinga
Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance - Yahoo Finance
Reported delays to FDA reviews under new fast-track program - The Pharma Letter
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
Klein Hersh Recruits CHRO for Disc Medicine - Hunt Scanlon Media
Disc Medicine (IRON) Stock Declines Amid Market Movement - GuruFocus
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - TradingView — Track All Markets
Disc Medicine (IRON) Faces Review Delay for Rare Disease Drug - GuruFocus
Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review - Investing.com South Africa
Stifel remains bullish on Disc Medicine stock despite potential FDA delay - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Shares Gap DownShould You Sell? - MarketBeat
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):